Inceptor Bio

Inceptor Bio, LLC, founded in 2020, is a biotechnology company dedicated to developing a diversified next-generation cell and gene therapy platform, including CAR-T, CAR-M, and CAR-NK/NKT, to provide treatments for cancers with unmet needs and refractory conditions. By collaborating with universities, medical centers, and industry leaders, Inceptor Bio plans to advance discovery-stage technologies into the clinical stage. Inceptor Bio is also investing in its advanced manufacturing platform, AMP+, as a purpose-built, capital-efficient, and scalable shared infrastructure to support the development of a diversified cell and gene therapy platform across various cell types.